1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca On Tagrisso's Milestone Advance Into Adjuvant Lung Cancer

 
• By Jessica Merrill

Oncology business unit head David Fredrickson talked to Scrip about Tagrisso’s approval as the first targeted adjuvant treatment for patients who have NSCLC with EGFR mutations.

Astrazeneca
AstraZeneca's Tagrisso is approved in adjuvant NSCLC • Source: Shutterstock

AstraZeneca PLC's lung cancer therapy Tagrisso (osimertinib) is the first targeted therapy approved by the US Food and Drug Administration for adjuvant treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, an early setting where treatment could make a substantial impact.

"In a year where good news is sometimes hard to come by, I think that this approval is incredibly great...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?